Probiotics and Antibiotics in the Correction of Neurodegenerative Diseases (Review)

УДК 615.017+615.331

DOI: 10.22138/2500-0918-2019-16-4-465-478

L.S. Korotovskikh

South–Ural State medical University, Chelyabinsk, Russian Federation

Abstract. Relevance. Currently, neurodegenerative diseases are a rapidly growing medical and social burden, the treatment of which is aimed at alleviating the symptoms of diseases and improving the quality of life of patients. The traditional targeted approach to the discovery of new drugs is quite time-consuming and lengthy, and also leads to a huge economic burden. An alternative paradigm for the discovery of new drugs is the reprofiling of existing drugs. Purpose of review. Consideration of the theoretical basis for the use of microbiota-directed therapy for neurodegenerative diseases. Materials and methods. Original studies published in scientometric databases — Scopus, Web of Science, Pub Med, RSCI — mainly over the last 5–7 years, were studied. Results. Increasingly, a connection is found between neurodegenerative diseases and changes in the microbiota. The potential of probiotic cultures and their metabolites are associated with the fact that they have a beneficial effect on the composition and function of the intestinal microbiota, restoring the complex dialogue between intestinal microbes and the host, and, ultimately, restoring the balanced axis of the microbiota-intestines-brain. Some antibiotics affect the pathological conditions of central nervous system disorders, including the glutamatergic system, oxidative stress, and neuroinflammation. Findings. Recent studies showing the potential effect of probiotics and antibiotics on the alleviation of the symptoms of various neurological disorders, in particular, Parkinson's disease and Alzheimer's disease, seem to us promising in terms of changing the treatment strategy for these pathologies.

Keywords: probiotics, microbiota, an axis of microbiota-gut-brain; neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, antibiotics, ceftriaxone

Received 24.10.2019

For citation: Korotovskikh L.S. Probiotics and Antibiotics in the Correction of Neurodegenerative Diseases (Review). Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2019, Vol. 16, no. 4, pp. 465–478. DOI: 10.22138/2500-0918-2019-16-4-465-478 (In Russ)

REFERENCES
1. Cummings J. Disease modification and neuroprotection in neurodegenerative disorders. Transl. Neurodegener. 2017. 6: p/.25. DOI: 10.1186/s40035-017-0096-2
2. Kim T.W. Drug repositioning approaches for the discovery of new therapeutics for alzheimer’s disease. Neurotherapeutics. 2015. 12 (1): pp. 132–142. DOI: 10.1007/s13311-014-0325-7
3. Kramer P., Bressan P. Humans as Superorganisms: How Microbes, Viruses, Imprinted Genes, and Other Selfish Entities Shape Our Behavior. Perspect Psychol Sci. 2015. Jul.10(4): pp. 464-481.
4. Liang S., Wu X., Jin F. Gut-brain physiology: rethinking psychology from the microbiota-gut-brain axis. Frontiers in Integrative Neuroscience. 2018. 12: pp. 1–24
5. Shanahan F., van Sinderen D., O’Tool P. W., Stanton C. Feeding the microbiota: transducer of nutrient signals for the host. Gut. 2017. 66 (9): pp 1709–1717.
6. David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J. E., Wolfe B. E. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014. 505 (7484): pp..559–563. DOI: 10.1038/nature 12820
7. Daien C. I., Pinget G. V., Tan J. K., Macia L. Detrimental impact of microbiota-accessible carbohydrate deprived diet on gut and immune homeostasis: an overview. Front. Immunol. 2017. 8: p 548. DOI: 10.3389/fimmu.2017.00548
8. Koh A., De Vadder F., Kovatcheva-Datchary P., Backhed F. From dietary fiber to host physiology: short chain fatty acids as key bacterial metabolites. Cell 2016. 165: pp.1332–1345. DOI: 10.1016/j.cell.2016.05.041
9. Sonnenburg E. D., Smits S.A. Tikhonov M., Higginbottom S.K., Wingreen Sonnenburg J. L. Diet-induced extinctions in the gut microbiota compound over generations. Nature. 2016. p. 529: 212–215. DOI: 10.1038/nature16504
10. Suez J., Korem T., Zeevi D., Zilberman-Schapira G., Thaiss C. A., Maza O. et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014. 514: pp. 181–186. DOI: 10.1038/nature13793
11. Chassaing B., Koren O., Goodrich J. K., Poole A. C., Srinivasan S., Ley R. E. et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015. 519: pp. 92–96. DOI: 10.1038/nature14232
12. Jin Y., Wu S., Zeng Z., Fu Z. Effects of environmental pollutants on gut microbiota. Environ. Pollut. 2017. 222: pp. 1–9. DOI: 10.1016/j.envpol.2016.11.045
13. Hallgren M., Herring M. P., Owen N., Dunstan D., Ekblom O., Helgadottir B. et al. Exercise, physical activity, and sedentary behavior in the treatment of depression: broadening the scientific perspectives and clinical opportunities. Front. Psychiatry. 2016. 7: p. 36. DOI: 10.3389/fpsyt.2016.00036
14. Zhao L., Zhang C. Microbiome: keeping rhythm with your gut. Nat. Microbiol. 2017. 26: p. 16273. DOI: 10.1038/nmicrobiol.2016.273
15. Blaser M. J. Antibiotic use and its consequences for the normal microbiome. Science. 2016. 352: pp. 544–545. DOI: 10.1126/science.aad9358
16. Shenderov B.A, Golubev V.L., Danilov A.B., Prishchepa A.V. Gut human microbiota and neurodegenerative diseases. [Kishechnaya mikrobita cheloveka i nejrodegenerativnye zabolevaniya] Policlinic [Poliklinika] 2016, no 1-1: pp. 7-13. (InRuss.)
17. Xie A., Gao J., Xu L., Meng D. Shared mechanisms of neurodegeneration in alzheimer’s disease and parkinson’s disease. Biomed. Res. Int. 2014. 2014: p. 648740. DOI: 10.1155/2014/648740
18. Franco-Iborra S., Vila M., Perier, C. Mitochondrial Quality control in neurodegenerative diseases: focus on parkinson’s disease and huntington’s disease. Front. Neurosci. 2018. 12: p. 342. DOI: 10.3389/fnins.2018.00342
19. Friedland R. P., Chapman M. R. The role of microbial amyloid in neurodegeneration. PLoS Pathog. 2017. 13: e1006654. DOI: 10.1371/journal.ppat.1006654
20. Minter M. R., Hinterleitner R., Meisel M., Zhang C., Leone V., Zhang X. et al. Antibiotic-induced perturbations in microbial diversity during postnatal development alters amyloid pathology in an aged APPSWE/PS1DeltaE9 murine model of Alzheimer’s disease. Sci. Rep. 2017. 7: p. 10411. DOI: 10.1038/s41598-017-11047-w
21. Hu X., Wang T., Jin, F. Alzheimer’s disease and gut microbiota. Sci. China Life Sci. 2016. 59 (10): pp. 1006–1023. DOI: 10.1007/s11427-016-5083-9
22. Westfall S., Lomis N., Kahouli I., Dia S. Y., Sing, S. P., Prakash S. Microbiome, probiotics and neurodegenerative diseases: decipheringthe gut brain axis. Cell. Mol. Life Sci. 2017. 74: pp. 3769–3787. DOI: 10.1007/s00018-017- 2550-9
23. Scheperjans F., Aho V., Pereira P.A., Koskinen K., Paulin L., Pekkonen E. et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015. 30(3): pp. 350-358.
24. Petrov V.A., Saltykova I.V., ZHukova I.A., Alifirova V.M., ZHukova N.G., Dorofeeva YU.B. et al. Study of intestinal microbiota in Parkinson's disease. [Issledovanie mikrobioty kishechnika pri bolezni Parkinsona] Bulletin of Experimental Biology and Medicine [Byulleten' eksperimental'noj biologii i mediciny]. 2016. Vol. 162 (12): pp. 700-703. (InRuss.)
25. Sampson T.R., Debelius J.W., Thron T., Janssen S., Shastri G.G., Ilhan Z.E. et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016.167(6): pp. 1469-1480 e1412.
26. Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun. 2018 May. 70: pp. 48-60. DOI: 10.1016/j.bbi.2018.02.005.
27. Caputi V., Giron M.C. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease. Int J Mol Sci. 2018 Jun 6. 19(6): p. 1689. DOI: 10.3390/ijms19061689.
28. Rietdijk C.D., van Wezel R.J., Garssen J., Kraneveld A.D. Neuronal toll-like receptors and neuro-immunity in Parkinson’s disease, Alzheimer’s disease and stroke. Neuroimmunol. Neuroinflamm. 2016. 3: pp. 27–37. DOI: 10.20517/2347-8659.2015.28
29. Tamtaji O.R., Taghizadeh M., Daneshvar Kakhaki R., Kouchaki E., Bahmani F., Borzabadi S. et al. Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019. 38 (3): pp. 1031 – 1035.
30. Sanders M.E., Benson A., Lebeer S., Merenstein D.J., Klaenhammer T.R. Shared mechanisms among probiotic taxa: Implications for general probiotic claims. Curr. Opin. Biotechnol. 2018. 49:207–216. DOI: 10.1016/j.copbio.2017.09.007.
31. Kobayashi Y., Sugahara H., Shimada K., Mitsuyama E., Kuhara T., Yasuoka A. et al. Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease. Sci Rep 2017. 7(1): p. 13510. DOI: 10.1038/s41598-017-13368-2
32. Akbari E., Asemi Z., Daneshvar Kakhaki R., Bahmani F., Kouchaki E., Tamtaji O.R. et al. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci 201.p 68: p.256. DOI: 10.3389/fnagi.2016.00256
33. Barboza J.L., Okun M.S., Moshiree B. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease. Expert Opin. Pharmacother. 2015. 16: pp. 2449–2464. DOI: 10.1517/14656566.2015.1086747.
34. Parashar A., Udayabanu M. Gut microbiota: Implications in Parkinson’s disease. Parkinsonism Relat. Disord. 2017. 38: pp. 1–7. DOI: 10.1016/j.parkreldis.2017.02.002.
35. Huang C. K., Chang Y. T., Amstislavskaya T. G., Tikhonova M. A., Lin C. L., Hung C. S. et al. Synergistic effects of ceftriaxone and erythropoietin on neuronal and behavioral deficits in an MPTP-induced animal model of Parkinson’s disease dementia. Behav. Brain Res. 2015. 294: pp. 198–207. DOI: 10.1016/j.bbr.2015.08.011
36. Chotibut T., Davis R. W., Arnold J. C., Frenchek Z., Gurwara S., Bondada V. et al. Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson’s model. Mol. Neurobiol. 2014. 49: pp. 1282–1292. DOI: 10.1007/s12035-013-8598-0
37. Bisht R., Kaur B., Gupta H., Prakash A. Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson’s disease in rats. Neurotoxicology. 2014. 44: pp. 71–79. DOI: 10.1016/j.neuro.2014.05.009
38. Kaur B., Prakash A. Ceftriaxone attenuates glutamate-mediated neuro-inflammation and restores BDNF in MPTP model of Parkinson’s disease in rats. Pathophysiology 2017. 24: pp. 71–79. DOI: 10.1016/j.pathophys.2017.02.001
39. Ho Y., Weng J., Lin C., Shen M., Li H., Liao W. et al. Ceftriaxone treatment for neuronal deficits: a histological and MEMRI study in a rat model of dementia with lewy bodies. Behav. Neurol. 2018: p. 4618716. DOI: 10.1155/2018/4618716
40. Ho S. C., Hsu C. C., Pawlak C. R., Tikhonova M. A., Lai T. J., Amstislavskaya T. G. et al. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson’s disease rat model. Behav. Brain Res. 2014. 268: pp. 177–184. DOI: 10.1016/j.bbr.2014.04.022
41. Zumkeh J., Rodriguez-Ortiz C. J., Cheng D., Kieu Z., Wai T., Hawkins C. et al. Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer’s disease. Neurobiol. Aging 2015. 36: pp. 2260–2271. DOI: 10.1016/j.neurobiolaging.2015.04.005
42. Tikhonova M. A., Ho S. C., Akopyan A. A., Kolosova N. G., Weng J. C., Meng W. Y. et al. Neuroprotective effects of ceftriaxone treatment on cognitive and neuronal deficits in a rat model of accelerated senescence. Behav. Brain Res. 2017. 3306: pp. 8–16. DOI: 10.1016/j.bbr.2017.05.002
43. Akina S., Thati M., Puchchakayala G. Neuroprotective effect of ceftriaxone and selegiline on scopolamine induced cognitive impairment in mice. Adv. Biol. Res. 2013. 7: pp. 266–275. DOI: 10.5829/idosi.abr.2013.7.6.75119
44. Cudkowicz M. E., Titus S., Kearney M., Yu H., Sherman A., Schoenfeld D. et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014. 13: pp. 1083–1091. DOI: 10.1016/S1474-4422(14)70222-4
45. Sari Y., Prieto A. L., Barton S. J., Miller B. R., Rebec G. V. Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington’s disease. J. Biomed. Sci. 2010. 17: p. 62. DOI: 10.1186/1423-0127-17-62
46. Annweiler C., Brugg B., Peyrin J. M., Bartha R., Beauchet, O. Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. Neurobiol. Aging 2014. 35: pp. 331–335. DOI: 10.1016/j.neurobiolaging.2013.07.029
47. Divito C. B., Underhill S. M. Excitatory amino acid transporters: roles in glutamatergic neurotransmission. Neurochem. Int. 2014. 73: pp. 172–180. DOI: 10.1016/j.neuint.2013.12.008
48. Scofield M. D., Kalivas P. W. Astrocytic dysfunction and addiction: consequences of impaired glutamate homeostasis. Neuroscientist 2014. 20: pp. 610–622. DOI: 10.1177/1073858413520347
49. Bai X., Zhang C., Chen A., Liu W., Li J., Sun Q. et al. Protective effect of edaravone on glutamate-induced neurotoxicity in spiral ganglion neurons. Neural Plast. 2016: p. 4034218. DOI: 10.1155/2016/4034218
50. Lee S.G., Su Z.Z., Emdad L., Gupta P., Sarkar D., Borjabad A., et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J. Biol. Chem. 2008. 283: pp. 13116–13123. DOI: 10.1074/jbc.M707697200
51. Shah S. A., Amin F. U., Khan M., Abid M. N., Rehma, S. U., Kim T. H. et al. Anthocyanins abrogate glutamate-induced AMPK activation, oxidative stress, neuroinflammation, and neurodegeneration in postnatal rat brain. J. Neuroinflammation. 2016. 13: p.286. DOI: 10.1186/s12974-016-0752-y
52. Yang Q., Zhou J. Neuroinflammation in the central nervous system: symphony of glial cells. Glia. 2019 Jun. 67(6): pp. 1017-1035. DOI: 10.1002/glia.23571.
53. Yimer E. M., Surur A., Wondafrash D. Z., Gebre A. K. The effect of metformin in experimentally induced animal models of epileptic seizure. Behav. Neurol. 2019 Feb 4. 2019: p. 6234758. DOI: 10.1155/2019/6234758
54. Ruzza P., Siligardi G., Hussain R., Marchiani A., Islami M., Bubacco L. et al. Ceftriaxone blocks the polymerization of a-synuclein and exerts neuroprotective effects in vitro. ACS Chem. Neurosci. 2014. 5: pp. 30–38. DOI: 10.1021/cn400149k

Author
Korotovskih Larisa Stepanovna
Federal State Budgetary Educational Institution of Higher Education “South – Ural State medical University” of Ministry of Healthcare of the Russian Federation, Chelyabinsk, Russian Federation
Candidate of Medical Sciences, Associate Professor of the Department of Pharmacology
454092, Rossijskaya Federaciya, Ural'skij Federal'nyj okrug, CHelyabinskaya oblast', g. CHelyabinsk, ul. Vorovskogo, 64 
korotovenik@gmail.com